Signature Equity Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
Other funds holding LLY
Signature Equity Partners's LLY Position: Q2 2026 in Review
Signature Equity Partners increased its Eli Lilly (LLY) stake by 17% in Q2 2026, buying an estimated $108K and bringing the position to 730 shares worth $875K. The position accounts for 0.4% of the portfolio, ranked #59.
Signature Equity Partners first reported a position in LLY in Q4 2025 and has held it in 3 quarters since. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Signature Equity Partners held 730 shares of Eli Lilly worth $875K as of Q2 2026.
- Signature Equity Partners bought 106 Eli Lilly shares in Q2 2026, an estimated $108K.
- Eli Lilly made up 0.4% of Signature Equity Partners's portfolio in Q2 2026, its #59 holding.
- Signature Equity Partners first reported a position in Eli Lilly in Q4 2025 and has held it in 3 quarters since.
- 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.